On August 27, Hinge Health, Inc. rose 5.09% in regular trading, trading at $95.56 per share with turnover of $23.76 million.

The rally continues to be driven by the company's strong Q2 earnings report and a wave of analyst target price increases. Hinge Health reported Q2 revenue of $212.8 million, up from $139.1 million a year earlier and beating the consensus estimate of $201.5 million. The company raised its full-year revenue guidance to $856-$860 million, well above the Street estimate of $822.2 million, while Q3 revenue guidance of $223-$225 million also exceeded the $211.5 million analyst expectation.

Following the results, Truist raised its price target from $85 to $112 maintaining a Buy rating, while Morgan Stanley lifted its target from $108 to $117 maintaining an Overweight rating. The average analyst target price now stands at $101.67, signaling continued institutional confidence in the company's growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)